The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval of Bayer’s Lynkuet (elinzanetant), a dual neurokinin-1 and neurokinin-3 receptor antagonist for treating moderate to severe vasomotor symptoms of menopause. This non-hormonal oral treatment joins a growing class addressing hot flashes, an unmet need especially for women contraindicated for hormonal therapies. Lynkuet has already been approved in the UK, Canada, Australia, and Switzerland, and the CHMP endorsement advances its broader European availability.